A prospective, single arm, multicentric clinical study to evaluate the safety and efficacy ofHERBOVIR syrup in subjects with upper respiratory tract infection along with standard of care

VENKAT PHARMA0 个研究点目标入组 0 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1.Subjects aged 18-65 years of age and of either sex
•2.subjects who were disposed to give consent to the study and willing for follow-up
•3.Subjects who are willing to sign ICF
•4.Clinical signs and symptoms of an URTI with a duration of up to 24 hours accompanied with or without fever 37.5 C (axillary body temperature) or higher
•5.At least 1 of 3 types of URTI symptoms â?? Nasal (plugged nose, runny nose, sneezing), Pharyngeal (scratchy throat, sore throat, pharyngeal hyperaemia), Cough (ordinary cough without suspicion of acute lower respiratory tract disease). At least 1 of 5 general symptoms â?? feeling tired, weakness, body ache, irritable or whiney,or less active
•6.Not be in need of hospitalized medical care at screening

•1.Age less than 18 years and more than 65 years
•2.Pregnancy
•3.Severe or complicated course of URTI.
•4.Signs of acute lower respiratory tract disease.
•5.Daily use of antibiotics, steroids and cytotoxic agents.
•6.Any uncontrolled systemic disease, infection
•7.Those with serious Cardiovascular, Cerebrovascular, Respiratory, Liver or Renal disease• or any other disorder

发起方

VENKAT PHARMA